Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 33% Improvement Relative Risk HCQ  Martinez-Lopez et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 167 patients in Spain Lower mortality with HCQ (not stat. sig., p=0.2) c19hcq.org Martinez-Lopez et al., Blood Cancer J., Jun 2020 Favors HCQ Favors control

Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality

Martinez-Lopez et al., Blood Cancer Journal, doi:10.1038/s41408-020-00372-5
Jun 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19hcq.org
Retrospective 167 multiple myeloma patients in Spain, showing no significant difference in mortality with HCQ treatment in unadjusted results without group details.
Although the 33% lower mortality is not statistically significant, it is consistent with the significant 25% lower mortality [20‑29%] from meta analysis of the 250 mortality results to date.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 33.0% lower, RR 0.67, p = 0.20, treatment 47 of 148 (31.8%), control 9 of 19 (47.4%), NNT 6.4.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Martinez-Lopez et al., 30 Jun 2020, retrospective, Spain, peer-reviewed, median age 71.0, 25 authors.
This PaperHCQAll
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
Joaquín Martínez-López, María-Victoria Mateos, Cristina Encinas, Anna Sureda, José Ángel Hernández-Rivas, Ana Lopez De La Guía, Diego Conde, Isabel Krsnik, Elena Prieto, Rosalía Riaza Grau, Mercedes Gironella, María Jesús Blanchard, Nerea Caminos, Carlos Fernández De Larrea, María Alicia Senin, Fernando Escalante, José Enrique De La Puerta, Eugenio Giménez, Pilar Martínez-Barranco, Juan José Mateos, Luis Felipe Casado, Joan Bladé, Juan José Lahuerta, Javier De La Cruz, Jesús San-Miguel
Blood Cancer Journal, doi:10.1038/s41408-020-00372-5
There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73 hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients with COVID-19 admitted at six participating hospitals. Among MM and noncancer patients, median age was 71 years, and 57% of patients were male; 75 and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was moderate-severe in 77 and 89% of patients and critical in 8 and 4%, respectively. Supplemental oxygen was required by 47 and 55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required noninvasive/invasive ventilation. Inpatient mortality was 34 and 23% in MM and noncancer patients, respectively. Among MM patients, inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent prognostic factors on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies predictors of inpatient mortality among MM patients hospitalized with COVID-19.
Conflict of interest M.-V.M. has received honoraria for lectures and participation in advisory boards from Janssen, Celgene-BMS, Amgen, Takeda, Abbvie, GSK, Adaptive, Roche, Seatle Genetics, Pfizer, and Regeneron. J.M.-L. has received honoraria for participation in advisory boards from Novartis, Roche, BMS, Adaptive, Incyte, Amgen, and Janssen-Cilag. J.S.-M. has received honoraria for lectures and advisory boards from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Merck, Novartis, Takeda, Sanofi, and Roche. J.B. has received honoraria for lectures and advisory boards from Janssen, Celgene, Amgen, Takeda, and Oncopeptides. J.J.L. has received honoraria for lectures and advisory boards from Janssen, Celgene, Amgen, and Takeda. A.L. has received honoraria for advisory boards from Celgene, Amgen, and Janssen. P.M.-B. has received honoraria for advisory boards from Amgen. A.S. has received honoraria for advisory boards from Takeda, BMS, MSD, Sanofi, Roche, Novartis, Janssen, and Sandoz, and for a consultancy from Takeda, BMS, Novartis, Celgene, Janssen, Gilead, and Sanofi, and has received honoraria as a member of a Speakers Bureau for Takeda. F.E. has received honoraria for advisory boards from Celgene and Amgen. E.P.P. has received honoraria for advisory boards from Amgen and for lectures from BMS/Celgene and Janssen. C.F.d.L. has received honoraria for advisory boards from BMS/Celgene, Amgen, Takeda, and Janssen. L.F.C. reports honoraria for lectures from and membership on..
References
Barragan, Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy, Haematologica
Basler, Lauer, Beck, Groettrup, The proteasome inhibitor bortezomib enhances the susceptibility to viral infection, J. Immunol
Bhatraju, Covid-19 in critically Ill patients in the Seattle region-case series, N. Engl. J. Med
Blimark, Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients, Haematologica
Chen, Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies, Ann. Hematol
Cheng, Kidney disease is associated with in-hospital death of patients with COVID-19, Kidney Int
Cook, Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy, Br. J. Haematol, doi:10.1111/bjh.16874
De Alicante, Gutiérrez Pastor, Del Bierzo, Miguel, de Cabo López
Di Ciaccio, Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic, Intern. Med. J, doi:10.1111/imj.14859
Feng, Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma, Clin. Cancer Res
Fernández-Ruiz, COVID-19 in solid organ transplant recipients: a single-center case series from Spain, Am. J. Transplant, doi:10.1111/ajt.15929
Grasselli, Pesenti, Cecconi, Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response, J. Am. Med. Assoc, doi:10.1001/jama.2020.4031
Guan, Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med
Hayden, Van Der Windt, Cartwright, Côté, Bombardier, Assessing bias in studies of prognostic factors, Ann. Intern. Med
Hospital San, Murillo, Universitario, Sanchinarro, Pérez De Oteyza et al., Hospital General de Ciudad Real
Hungria, Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel-ABHH Monoclonal Gammopathies Committe, Hematol. Transfus Cell Ther, doi:10.1016/j.htct.2020.1005.1001
Lee, COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study, Lancet
Liang, Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China, Lancet Oncol
Martín-Moro, Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies, Br. J. Haematol, doi:10.1111/bjh.16801
Mian, Caring for older adults with multiple myeloma during the COVID-19 pandemic: perspective from the international forum for optimizing care of older adults with myeloma, J. Geriatr. Oncol
Moons, Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration, Ann. Intern. Med
Nahi, Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma, PLoS ONE
Saleh, Sher, Gertz, Multiple myeloma in the time of COVID-19, Acta Haematol, doi:10.1159/000507690
Sauerbrei, Taube, Mcshane, Cavenagh, Altman, Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration, J. Natl Cancer Inst
Terpos, Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network, Leukemia, doi:10.1038/s41375-41020-40876-z
Universitario De Cabueñes, Esther, García, Hospital, Universitario et al., None
Universitario, Elena, Naya Errea, Del Tajo, Sainz et al., Hospital Universitario Virgen de la Arrixaca
Wu, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern. Med
Zhang, Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China, Ann. Oncol
Zhang, First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab, Blood Adv
Zhou, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit